Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal
Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...
Novo Nordisk defends disappointing next-gen obesity drug: ‘It will be an important product'
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.
University of Sussex21h
School of Global Studies
Our four departments are in the UK's top 20 (QS University Rankings 2024). The School of Global Studies is a global hub at the heart of Sussex University. Our engaged research and critical pedagogy ...